Acceleron completes target enrollment in phase 2 trial of Sotatercept in PAH

This article was originally published here

The Company now expects to report top-line results during the first quarter of 2020. “We’re thrilled with PULSAR’s rapid enrollment over the past 12 months, which underscores the

The post Acceleron completes target enrollment in phase 2 trial of Sotatercept in PAH appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply